VCs Compare Notes On Biotech Investment Landscape In 2016
This article was originally published in Scrip
Executive Summary
So far in 2016 the number and value of deals by pharma and biotech companies in the private sector has dropped significantly compared to recent years – but money is still there for start-ups with innovative technology and robust science, say venture capitalists.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.